Latest news with #Neogen
Business Wire
a day ago
- Business
- Business Wire
Deadline Alert: Neogen Corporation (NEOG) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming September 16, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Neogen Corporation ('Neogen' or the 'Company') (NASDAQ: NEOG) common stock between January 5, 2023 and June 3, 2025, inclusive (the 'Class Period'). IF YOU SUFFERED A LOSS ON YOUR NEOGEN INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS. What Happened? On January 10, 2025, Neogen disclosed that its second quarter GAAP net income was significantly negative due to a $461 million non-cash goodwill impairment charge related to its acquisition of the 3M Company ('3M'). The Company also revised its full year outlook, cutting revenue and EBITDA guidance. Further, the Company also revealed that as of November 30, 2024, it had material weaknesses in its internal control over financial reporting. On this news, Neogen's stock price fell $0.71, or 5.4%, to close at $12.36 per share on January 10, 2025, thereby injuring investors. Then, on April 9, 2025, Neogen disclosed that quarterly revenue had fallen 3.4% due, in part, to integration issues. The Company also further cut its full year revenue and EBITDA outlook and revealed that its CEO would be stepping down. On this news, Neogen's stock price fell $2.02, or 28.7%, to close at $5.02 per share on April 9, 2025. Then, on June 4, 2025, Neogen disclosed that, while its fourth quarter fiscal 2025 financial results would be 'materially approximate [to] where [the Company] had put [its] guide,' it 'would expect EBITDA margin to probably be around the high-teens' compared to the previous quarter's 22%. The Company explained that EBITDA margins would likely 'be in the low-20s, if not for the elevated inventory write-offs.' On this news, Neogen's stock price fell $1.04, or 17.3%, to close at $4.96 per share on June 4, 2025, thereby injuring investors further. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the integration with 3M was plagued with inefficiencies that Defendants knew would necessitate a goodwill impairment and would impact capital expenditures, revenues, and EBITDA margins; and (2) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Neogen common stock during the Class Period, you may move the Court no later than September 16, 2025 to request appointment as lead plaintiff in this putative class action lawsuit. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150, Toll-Free: 888-773-9224 Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. If you inquire by email, please include your mailing address, telephone number and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Yahoo
2 days ago
- Business
- Yahoo
Baxter (BAX) Reports Earnings Tomorrow: What To Expect
Healthcare company Baxter International (NYSE:BAX) will be reporting earnings this Thursday before market hours. Here's what to expect. Baxter beat analysts' revenue expectations by 1.9% last quarter, reporting revenues of $2.63 billion, up 5.4% year on year. It was a very strong quarter for the company, with a solid beat of analysts' constant currency revenue estimates and an impressive beat of analysts' EPS estimates. Is Baxter a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Baxter's revenue to grow 4.7% year on year to $2.82 billion, in line with the 4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.61 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Baxter has missed Wall Street's revenue estimates six times over the last two years. Looking at Baxter's peers in the medical devices & supplies - diversified segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts' expectations by 3.4%, and Neogen reported a revenue decline of 4.8%, topping estimates by 1.3%. Boston Scientific traded up 2.9% following the results. Read our full analysis of Boston Scientific's results here and Neogen's results here. Investors in the medical devices & supplies - diversified segment have had fairly steady hands going into earnings, with share prices down 1.8% on average over the last month. Baxter is down 5.2% during the same time and is heading into earnings with an average analyst price target of $37.09 (compared to the current share price of $28.70). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Star
2 days ago
- Health
- The Star
QuickCheck: Does salmon DNA improve your skin?
Salmon DNA is apparently beneficial for your skin. - Pix courtesy of Nick Longrich (CC BY-SA 4.0). NEW skincare technology is being developed each day, especially from countries like South Korea, Japan, and France who have been in the skincare game for years. Among the latest trending ingredients is salmon DNA, commercially introduced in the 2010s by brands such as Pluryal (Italy), Neogen (Korea), and Biopelle (US). But does salmon DNA actually improve skin over time? Verdict: TRUE Yes, the benefits are real. Clinical research and dermatological use confirm that salmon DNA, specifically polydeoxyribonucleotide (PDRN) which is derived from Salmon DNA, can help repair skin, reduce wrinkles, and improve hydration — when applied or injected properly. PDRN promotes tissue regeneration and stimulates collagen production. A 2017 study reported that it supports wound healing and skin renewal, making it effective in anti-aging treatments. It also has hygroscopic, or water-binding, properties that help the skin retain moisture. Dermatologists highlight that marine-derived DNA fragments can strengthen the skin barrier, boosting hydration and elasticity. Salmon DNA is commonly used in microneedling and injectable treatments, where doctors have observed noticeable improvements in skin texture, firmness, and fine lines over time. In short: the buzz around salmon DNA isn't just hype — it's backed by science. Just make sure treatments are administered by licensed professionals, and you could be looking at smoother, stronger, and more hydrated skin. References: 1. health/salmon-sperm-facial 2. science/article/pii/ S2096691122000723 3. articles/PMC11311621/
Business Wire
3 days ago
- Business
- Business Wire
Law Offices of Frank R. Cruz Encourages Neogen Corporation (NEOG) Investors to Inquire About Securities Fraud Class Action
LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Neogen Corporation ('Neogen' or the 'Company') (NASDAQ: NEOG) common stock between , inclusive (the 'Class Period'). Neogen investors have until September 16, 2025 to file a lead plaintiff motion. Law Offices of Frank R. Cruz Encourages Neogen Corporation (NEOG) Investors To Inquire About Securities Fraud Class Action Share IF YOU SUFFERED A LOSS ON YOUR NEOGEN CORPORATION (NEOG) INVESTMENTS, CLICK HERE TO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT. You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at info@ by telephone at (310) 914-5007, or visit our website at What Happened? On January 10, 2025, Neogen disclosed that its second quarter GAAP net income was significantly negative due to a $461 million non-cash goodwill impairment charge related to its acquisition of the 3M Company ('3M'). The Company also revised its full year outlook, cutting revenue and EBITDA guidance. Further, the Company also revealed that as of November 30, 2024, it had material weaknesses in its internal control over financial reporting. On this news, Neogen's stock price fell $0.71, or 5.4%, to close at $12.36 per share on January 10, 2025, thereby injuring investors. Then, on April 9, 2025, Neogen disclosed that quarterly revenue had fallen 3.4% due, in part, to integration issues. The Company also further cut its full year revenue and EBITDA outlook and revealed that its CEO would be stepping down. On this news, Neogen's stock price fell $2.02, or 28.7%, to close at $5.02 per share on April 9, 2025. Then, on June 4, 2025, Neogen disclosed that, while its fourth quarter fiscal 2025 financial results would be 'materially approximate [to] where [the Company] had put [its] guide,' it 'would expect EBITDA margin to probably be around the high-teens' compared to the previous quarter's 22%. The Company explained that EBITDA margins would likely 'be in the low-20s, if not for the elevated inventory write-offs.' On this news, Neogen's stock price fell $1.04, or 17.3%, to close at $4.96 per share on June 4, 2025, thereby injuring investors further. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the integration with 3M was plagued with inefficiencies that Defendants knew would necessitate a goodwill impairment and would impact capital expenditures, revenues, and EBITDA margins; and (2) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. Contact Us To Participate or Learn More: If you purchased Neogen common stock, wish to learn more about this action, or have any questions concerning this announcement or your rights or interests with respect to these matters, please click HERE or contact us at: Law Offices of Frank R. Cruz 2121 Avenue of the Stars, Suite 800 Telephone: 310-914-5007 Email: info@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
3 days ago
- Business
- Business Wire
Neogen® Expands its Pathogen Portfolio and Environmental Monitoring Solutions with a New Rapid Test for Listeria
LANSING, Mich.--(BUSINESS WIRE)--Neogen Corporation (NASDAQ: NEOG) today announced the launch of Molecular Detection Assay - Listeria Right Now™, a rapid, enrichment-free solution for detecting Listeria species in the environment. The new tool is being introduced at the 2025 International Association for Food Protection (IAFP) Annual Meeting, taking place July 27–30 at the Huntington Convention Center in Cleveland, Ohio. 'When it comes to Listeria, every hour counts. Listeria Right Now was designed to give food safety teams answers fast enough to act before a risk becomes a recall,' said Dr. Jason Lilly, Chief Scientific Officer at Neogen. Share With a time-to-result of approximately two hours, Listeria Right Now helps enable food safety professionals to make faster, more informed sanitation decisions without compromising accuracy or requiring complex laboratory infrastructure. 'When it comes to Listeria, every hour counts. Listeria Right Now was designed to give food safety teams answers fast enough to act before a risk becomes a recall,' said Dr. Jason Lilly, Chief Scientific Officer at Neogen. 'The method is precise, practical, and easy to deploy. We're excited to show how it can strengthen environmental monitoring programs in real-world settings.' Key Benefits of Listeria Right Now Streamlined, user-friendly testing process Delivers results in approximately two hours No enrichment required Uniquely designed sampling device that is easy to use for a variety of surface types Enables same-day verification and corrective response within two hours Built for Efficiency from Start to Finish Listeria Right Now pairs a user-friendly sample collection device designed to efficiently swab surfaces up to 12'x 12' and access narrow cracks and crevices, with an innovative reagent system. Each reaction tube includes blue, color-coded pellets that contain all of the reagents necessary for detection. These pellets reconstitute easily when pipetted, helping to streamline lab workflow and improve consistency. Listeria Right Now is powered by Neogen's Molecular Detection System, which features intuitive software, color-coded assays for better tracking, and the ability to test up to 96 samples per run. The system supports simultaneous testing across multiple qualitative assays, enabling labs to maintain workflow flexibility without added complexity. Solving Real-World Food Safety Challenges Traditional Listeria detection methods often require 24 to 48 hours and may involve multiple tools depending on surface type and testing needs. For processors in dairy, produce, beef, and ready-to-eat segments, these delays can disrupt workflows and elevate contamination risk. Listeria Right Now simplifies the detection process and enables interventions to happen during the same production shift. Built for global applicability, Listeria Right Now offers a practical, high-impact solution for diverse food production environments worldwide, while also supporting the evolving regulatory expectations around Listeria monitoring in the U.S. Live Demonstrations at IAFP 2025 Neogen will be showcasing Listeria Right Now at Booth #511 at IAFP 2025. Attendees can experience live demonstrations and speak with Neogen experts about how the system complements the company's broader food safety diagnostics portfolio. To learn more or schedule a demonstration, visit or contact your Neogen representative. About Neogen Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.
